Related Experiment Video
Updated: Jul 9, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Should Familial Hypercholesterolaemia Be Included in the UK Newborn Whole Genome Sequencing Programme?
Steve E Humphries1, Uma Ramaswami2, Neil Hopper3
1Centre for Cardiovascular Genetics, Rayne Building, 5 University Street, University College London, London, United Kingdom, WC1E 6JJ.
Insights
Familial hypercholesterolaemia (FH) should be included in the UK Newborn Genomes Programme (NGP). Early detection via whole genome sequencing (WGS) enables timely treatment, improving health outcomes for infants with this inherited condition.
Area of Science:
- Genomics and Genetic Screening
- Public Health Initiatives
- Cardiovascular Disease Prevention
Background:
- The UK National Health Service (NHS) is launching a Newborn Genomes Programme (NGP).
- This program aims to identify infants with treatable inherited disorders using whole genome sequencing (WGS).
- Familial hypercholesterolaemia (FH) is a key focus for potential inclusion.
Purpose of the Study:
- To evaluate Familial Hypercholesterolaemia (FH) against the four key principles for inclusion in the Newborn Genomes Programme (NGP).
- To determine if FH meets the criteria for genetic screening in newborns.
Main Methods:
- Assessment of FH against established criteria for newborn screening programs (Wilson and Jungner criteria).
- Evaluation of FH based on four specific principles: reliable genetic detection, risk of early heart disease, benefit of early intervention, and equitable access to treatment.
Main Results:
- Principle A: Genetic variants causing FH are reliably detectable.
- Principle B: Individuals with FH variants face a high risk of early heart disease without diagnosis and treatment.
- Principle C: Early intervention significantly improves outcomes for children with FH.
- Principle D: Recommended interventions for FH are equitably accessible.
Conclusions:
- Familial Hypercholesterolaemia (FH) meets all four principles required for inclusion in the Newborn Genomes Programme (NGP).
- FH also satisfies the Wilson and Jungner criteria for screening programs.
- FH is strongly recommended for inclusion in the Newborn Genomes Programme for early detection and intervention.
Purpose Of Review:
The UK National Health Service (NHS) has recently announced a Newborn Genomes Programme (NGP) to identify infants with treatable inherited disorders using whole genome sequencing (WGS). Here, we address, for familial hypercholesterolaemia (FH), the four principles that must be met for the inclusion of a disorder in the NGP.
Recent Findings:
Principle A: There is strong evidence that the genetic variants causing FH can be reliably detected. Principle B: A high proportion of individuals who carry an FH-causing variant are likely to develop early heart disease if left undiagnosed and not offered appropriate treatment. Principle C: Early intervention has been shown to lead to substantially improved outcomes in children with FH. Principle D: The recommended interventions are equitably accessible for all. FH meets all the Wilson and Jungner criteria for inclusion in a screening programme, and it also meets all four principles and therefore should be included in the Newborn Genomes Programme.
More Related Videos
09:30Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Animal Mitochondrial Genetics